Results 111 to 120 of about 194,150 (247)
iMeta, Volume 5, Issue 5, October 2026.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
ObgyniaIntroduction: Adenomyosis impairs fertility through chronic inflammation and endometrial damage. While IVF with GnRH modulation is used to improve outcomes, no universal protocol exists.
Sofi Sumarlin +4 more
doaj +1 more source
, 2011 Increasing evidence supports GnRH agonists to be an effective treatment to preserve ovarian function during chemotherapy, but the initial flare-up of FSH during the first week after GnRH agonist application still limits its use.
Kämmerer, Ulrike +11 more
core +1 more source
Iron and Other Metal Ions in Human Health and Disease
MedComm, Volume 7, Issue 10, October 2026.Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley +1 more source
Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent [PDF]
, 2012 D-amino acid substitutions at glycine postion 6 in GnRH-I decapeptide can possess super-agonist activity and enhanced in vivo pharmacokinetics. Agonists elicit growth-inhibition in tumorigenic cells expressing the GnRH receptor above threshold levels ...
Morgan, Kevin +2 more
core +4 more sources
Клинический разбор в общей медицинеStudy question. How does a gonadotrophin-releasing hormone (GnRH) agonist versus a GnRH antagonist protocol affect ovarian response when using an individualized fixed daily dose of follitropin delta for ovarian stimulation? Summary answer.
Rita Lobo +11 more
doaj +1 more source
Microsurgery, Volume 46, Issue 7, October 2026.ABSTRACT Background The internal mammary vessels are commonly used as recipient vessels for free flap breast reconstruction. However, inadequate arterial flow may be encountered intraoperatively. This hypothesis‐generating study evaluated the safety and feasibility of activated clotting time (ACT)‐guided systemic heparinization as one component of a ...
Kazuhiro Tsunekawa +2 more
wiley +1 more source
Binding of WT and R31C GnRH to the GnRH receptor (GnRH-R).
, 2013 (A) COS-7 cells were transiently transfected with a human GnRH-R DNA construct and incubated with a 125I-labeled GnRH agonist in the presence of indicated concentrations of WT GnRH or R31C GnRH. IC-50 values are WT GnRH, 2.8×10−9 M and R31C GnRH, 8.50×10−
Regis Bobe (437214) +14 more
core +1 more source
Preclinical and Toxicology Studies of LPM7100328, a Novel Oral GnRH Antagonist
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT LPM7100328 is a novel oral GnRH antagonist being developed for the prevention of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. The studies presented herein reported assessment of safety in favor of human clinical trials.
Yao Wang +9 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.ABSTRACT Opioid receptor antagonists increase the plasma membrane density of μ‐opioid receptors (MOR) in vivo, thereby inducing “supersensitivity” to opioid agonists. This phenomenon increases the risk of overdose in patients that were being treated with naltrexone (Ntx), a popular MOR antagonist.
Stephen N. Grant +2 more
wiley +1 more source